ClinicalTrials.gg
CompletedNCT04196101RSVPUpdated Oct 30, 2023Results posted

A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects

A Phase 2 interventional study of EDP-938 and Placebo in Respiratory Syncytial Virus, sponsored by Enanta Pharmaceuticals, Inc. Completed at 29 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-30.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This was a randomized, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered EDP-938 in adults with RSV infection.

Read the detailed description

Subjects (aged 18 to 75 years, inclusive) with up to 48 hours of upper respiratory tract infection (URTI) symptoms who tested positive for respiratory syncytial virus (RSV) and negative for influenza virus by rapid testing (ie, Rapid Viral Screen). Subjects with stable asthma or chronic obstructive pulmonary disease (COPD) were allowed in the study.

Eighty-two (82) subjects were enrolled in this Phase 2b, randomized, double-blind, placebo-controlled, multicentre study of EDP-938 administered orally for the treatment of acute URTI with confirmed RSV infection in ambulatory adult subjects.

For each subject, the duration of study participation was approximately 2 weeks and consisted of 3 periods: Screening (occurs on Day1), Treatment (5 days), and Follow-up (9 days after last dose).

02

Conditions studied

  • Respiratory Syncytial Virus

Keywords

  • RSV
03

In context

Lead sponsor

Enanta Pharmaceuticals, Inc is the lead sponsor of 46 studies on the registry; 3 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An document must be signed and dated by the subject
  • Male or female individuals aged 18 to 75 years, inclusive.
  • Up to 48 hours of URTI symptoms with at least one of the following symptoms:

Nasal discharge, nasal congestion, malaise/tiredness, headache, sinus congestion, sneezing, sore throat, hoarseness, cough, shortness of breath, respiratory wheeze, earache, and/or symptoms of fever.

  • Positive for RSV infection and negative for influenza virus based on rapid diagnostic.
  • Must be willing and able to adhere to the study assessments, visit schedules, prohibitions, and restrictions, as described in this protocol.

Exclusion criteria

Exclusion Criteria:

  • SARS-CoV-2 positive within 28 days of Screening or at Screening following signature of full ICF.
  • Clinical evidence of a lower respiratory tract infection, as determined by the Investigator.
  • Anticipated need for hospitalization or emergency room care within 24 hours of Screening.
  • Receipt of systemic antiviral, antibacterial, antifungal, or antimycobacterial therapy within 7 days of Screening and for the duration of the study
  • Awareness of concomitant respiratory infections that are viral (other than RSV), bacterial, or fungal, including systemic bacterial or fungal infections, within 7 days of Screening.
  • Frailty scale score ≥4 at Screening.
  • History of chronic liver disease (eg, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, hepatitis, nonalcoholic steatohepatitis, and/or alcoholic liver disease); a history of biliary disease (eg, primary sclerosing cholangitis, cholecystitis, choledocholithiasis); or a history of portal hypertension. A diagnosis of hepatic steatosis (fatty liver) is not exclusionary.
  • Heart disease: any congenital heart disease, acute or chronic heart failure, ischemic heart disease, congenital long syndrome, or any clinical manifestation resulting in QT interval prolongation.
  • Neurological and neurodevelopmental disorders (including disorders of the brain, spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy [seizure disorders], stroke, muscular dystrophy, or spinal cord injury).
  • Malignant tumor or history of that may interfere with the aims of the study or a subject completing the study.
  • Prior receipt or the subject is waiting to receive a bone marrow, stem cell, or solid organ transplantation.
  • Diagnosis of cystic fibrosis.
  • Known positive , active hepatitis A virus infection, chronic virus infection, and/or current or treated virus infection.
  • Prior or planned ileal resection or bariatric surgery.
  • Pregnant or nursing female subjects.
  • History of alcohol addiction or current heavy alcohol use defined as: >14 standard drinks per week and/or ≥4 standard drinks per occasion for males and >7 standard drinks per week and/or ≥3 standard drinks per occasion for females. A standard drink is 12 oz of beer (5% alcohol), 5 oz table wine (12% alcohol), or 1.5 oz of spirits (40% alcohol).
  • Known or suspected, in the opinion of the Investigator, renal disease or renal impairment.
  • Twelve-lead demonstrating a QT interval corrected for heart rate according to Fridericia (QTcF) that is >500 msec or other abnormalities as judged by the Investigator at Screening.
  • Use of or intention to use excluded or medication(s) or supplements, including any medication known to be a moderate or potent inducer or inhibitor of the cytochrome P450 3A4 enzyme, within 14 days prior to Screening and for the duration of the study.
  • Receipt of ≥14 days of systemic immunomodulator therapy (eg, oral ) within 3 months of Screening.
  • Prior to the first dose of study drug and during study participation, the subject has received any vaccine, agent, or biological product within 30 days or 5 times the half-life, whichever is longer. Note: Influenza vaccination within 7 days of Screening is allowed.
  • Use of St John's wort within 28 days prior to the first dose of study drug and for the duration of the study.
  • History of or currently experiencing a medical condition or any other finding (including laboratory test results) that, in the opinion of the Investigator, might confound the results of the study; pose an additional risk in administering study drug to the subject; could prevent, limit, or confound the protocol-specified assessments; or deems the subject unsuitable for the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    EDP-938

    Subjects will take EDP-938 tablets (800 mg) once a day orally for 5 days

    Drug: EDP-938

  • Placebo comparator
    Placebo

    Subjects will take EDP-938 matching placebo tablets once a day orally for 5 days

    Drug: Placebo

Interventions

  • Four tablets daily for 5 days

  • DrugPlacebo

    Four tablets daily for 5 days

06

What researchers measure

Primary outcomes

  1. Total Symptom Score (TSS) Area Under the Curve (AUC)

    Assessed by the RSV Symptom Diary, including 13 items assessing the severity of RSV-related signs and symptoms. The diary uses a 4-point scale that consists of grading symptoms on a scale of 0 to 3 for each item, where Grade 0 is Absent, Grade 1 is Noticeable, Grade 2 is Bothersome but not preventing activity, and Grade 3 is Bothersome and interfering with activities. TSS is derived daily by summing of the 13 observed symptom grade values from Day 1 through Day 14 to generate the curve for analysis.

    Time frame: Day 1 through Day 14

Secondary outcomes

  1. RSV RNA Viral Load Area Under the Curve (AUC)

    RSV RNA viral load as measured in nasopharyngeal swab samples by RT-qPCR on Days 1 (Baseline, time 0), 3, 5, 9, and 14 to generate curve for analysis.

    Time frame: Day 1 through Day 14

  2. Number of Subjects With RSV RNA Viral Load Below Limit of Detection (LOD)

    Proportion of patients that have undetectable RSV RNA by qRT-PCR at Days 3, 5, 9 and 14.

    Time frame: Days 3, 5, 9 and 14

  3. Number of Participants With Adverse Events

    Time frame: Day 1 through Day 14

07

Results

Posted Oct 30, 2023

Participant flow

Participant flow — Overall Study
MilestoneEDP-938Placebo
Started4141
Completed3130
Not completed1011

Outcome measures

PrimaryTotal Symptom Score (TSS) Area Under the Curve (AUC)

Assessed by the RSV Symptom Diary, including 13 items assessing the severity of RSV-related signs and symptoms. The diary uses a 4-point scale that consists of grading symptoms on a scale of 0 to 3 for each item, where Grade 0 is Absent, Grade 1 is Noticeable, Grade 2 is Bothersome but not preventing activity, and Grade 3 is Bothersome and interfering with activities. TSS is derived daily by summing of the 13 observed symptom grade values from Day 1 through Day 14 to generate the curve for analysis.

Time frame:
Day 1 through Day 14
Reported as:
Mean · days x Score
Total Symptom Score (TSS) Area Under the Curve (AUC)
days x ScoreEDP-938Placebo
RSV A93.64 ± 97.18062.53 ± 40.310
RSV B73.75 ± 66.65278.34 ± 58.051
SecondaryRSV RNA Viral Load Area Under the Curve (AUC)

RSV RNA viral load as measured in nasopharyngeal swab samples by RT-qPCR on Days 1 (Baseline, time 0), 3, 5, 9, and 14 to generate curve for analysis.

Time frame:
Day 1 through Day 14
Reported as:
Mean · days x log10 copies/mL
RSV RNA Viral Load Area Under the Curve (AUC)
days x log10 copies/mLEDP-938Placebo
RSV RNA Viral Load Area Under the Curve (AUC)37.00 ± 24.00346.96 ± 21.002
SecondaryNumber of Subjects With RSV RNA Viral Load Below Limit of Detection (LOD)

Proportion of patients that have undetectable RSV RNA by qRT-PCR at Days 3, 5, 9 and 14.

Time frame:
Days 3, 5, 9 and 14
Reported as:
Count of participants · Participants
Number of Subjects With RSV RNA Viral Load Below Limit of Detection (LOD)
ParticipantsEDP-938Placebo
Day 352
Day 5125
Day 91511
Day 142623
SecondaryNumber of Participants With Adverse Events
Time frame:
Day 1 through Day 14
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsEDP-938Placebo
Number of Participants With Adverse Events1111

Adverse events

Collected over Participants were assessed over a period of two weeks; five days of dosing and nine days of follow-up.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EDP-9380/40 (0%)0/40 (0%)11/40 (27.5%)
Placebo0/41 (0%)0/41 (0%)11/41 (26.8%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventEDP-938Placebo
HeadacheNervous system disorders1/404/41
Urinary tract infectionInfections and infestations2/402/41
DiarrhoeaGastrointestinal disorders2/400/41
Oral herpesInfections and infestations0/402/41
Alanine aminotransferase increasedInvestigations1/401/41
Blood chloride decreasedInvestigations1/400/41
Blood cholesterol increasedInvestigations1/400/41
Blood creatine phosphokinase increasedInvestigations1/400/41
Blood sodium decreasedInvestigations1/400/41
Protein total decreasedInvestigations1/400/41

Baseline characteristics

The Safety (SAF) population included 81 subjects (98.8% of total randomized subjects) composed of all subjects who received at least one dose of study drug or placebo.

Age, Continuous
Age, Continuous(years)EDP-938PlaceboTotal
Mean47.0 ± 14.6147.8 ± 14.1447.4 ± 14.28
Sex: Female, Male
Sex: Female, Male(Participants)EDP-938PlaceboTotal
Female252651
Male151530
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EDP-938PlaceboTotal
Hispanic or Latino9716
Not Hispanic or Latino313465
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EDP-938PlaceboTotal
American Indian or Alaska Native101
Asian112
Native Hawaiian or Other Pacific Islander011
Black or African American235
White353671
More than one race000
Unknown or Not Reported101
08

Study locations

29 sites
  • Central Alabama Research
    Birmingham, Alabama 35209, United States
  • Cahaba Research Inc. - Birmingham
    Pelham, Alabama 35124, United States
  • Saint Joseph's Clinical Research
    Anaheim, California 92804, United States
  • Torrance Clinical Research Institute
    Lomita, California 90717, United States
  • Miami Clinical Research - ClinEdge - PPDS
    Miami, Florida 33155, United States
  • Pioneer Clinical Research LLC
    Bellevue, Nebraska 68005, United States
  • Meridian Clinical Research
    Norfolk, Nebraska 68701, United States
  • Clinical Research of South Nevada
    Las Vegas, Nevada 89121, United States
  • Carolina Research Center
    Shelby, North Carolina 28150, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Progressive Medicine of the Triad, LLC
    Winston-Salem, North Carolina 27103, United States
  • FMC Science
    Lampasas, Texas 76550, United States
  • Instituto Medico Platense
    Buenos Aires, B1900AVG, Argentina
  • Diagnostic and Consulting Center Aleksandrovska EOOD
    Sofia, Sofia-Grad 1431, Bulgaria
  • Medical Center Hera
    Sofia, Sofia-Grad 1510, Bulgaria
  • Multiprofile Hospital for Active Treatment Puls
    Blagoevgrad, 2700, Bulgaria
  • Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases - Haskovo EOOD
    Haskovo, 6300, Bulgaria
  • Medical Center Zdrave-1 OOD
    Kozloduy, 3320, Bulgaria
  • Medical Center Tara OOD
    Veliko Tarnovo, 5000, Bulgaria
  • Lakeland Clinical Trials - Waikato
    Hamilton, 3200, New Zealand
  • Lakeland Clinical Trials
    Rotorua, 3010, New Zealand
  • Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z.o.o
    Tarnów, Malopolskie 33-100, Poland
  • Specjalistyczny Osrodek Leczniczo-Badawczy Zbigniew Zegota
    Ostróda, 14-100, Poland
  • Clinical Projects Research SA pty Ltd
    Worcester, Western Cape 6850, South Africa
  • Communal Non-Profit Enterprise City Clinical Hospital #1 of Ivano-Frankivsk City Council
    Ivano-Frankivs'k, Ivano-Frankivsk 76014, Ukraine
  • Municipal Enterprise The 1st City Clinical Hospital of Poltava City Council
    Poltava, Poltavs'ka Oblast 36039, Ukraine
  • City Outpatient Clinic #9
    Kyiv, 3035, Ukraine
  • Medical Center of LLC Preventclinic
    Kyiv, 3035, Ukraine
  • Limited Liability Company Medical Center Consilium Medical
    Kyiv, 4050, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Jan 2022, 23 months.

Results were first posted in Oct 2023, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2019
First posted
Dec 12, 2019
StartActual
Jan 22, 2020
Primary completionActual
Jan 4, 2022
CompletionActual
Jan 4, 2022
Results first posted
Oct 30, 2023
Last update
Oct 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04196101
Collaborators
PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
Dec 12, 2019
Start date
Jan 22, 2020
Primary completion
Jan 4, 2022
Completion
Jan 4, 2022
Results posted
Oct 30, 2023
Last update
Oct 30, 2023

Study contacts

Scott Rottinghaus, MD
study director · Enanta Pharmaceuticals, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP-938

Start the discussion